LPA, lipoprotein(a), 4018

N. diseases: 340; N. variants: 49
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE This study suggests that Lp(a)-lowering by 50 mg/dL (105 nmol/L) short-term (ie, 5 years) may reduce CVD by 20% in a secondary prevention setting.High Lp(a) (Lipoprotein[a]) is associated with high risk of incident cardiovascular disease (CVD) in observational studies of individuals without CVD at baseline<sup>1, 2</sup>, that is, in a primary prevention setting. 31578080 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Age (OR: 1.07; 95% CI: 1.03, 1.10), male sex (OR: 1.95; 95% CI: 1.68, 2.23), hypertension (OR: 2.11; 95% CI: 1.64, 2.58), diabetes (OR: 1.95; 95% CI: 1.33, 2.57), body mass index (OR: 1.04; 95% CI: 1.03, 1.05), smoking (OR: 1.71; 95% CI: 1.30, 2.12), elevated lipoprotein(a) (OR: 1.90; 95% CI: 1.10, 2.71), low high-density lipoprotein cholesterol (OR: 1.39; 95% CI: 1.24, 1.53), and a family history of CVD (OR: 1.83, 95% CI: 1.58, 2.07) were found to be significant CVD risk factors in FH. 30527766 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Patients with metabolic syndrome (MetS) are at high risk of developing cardiovascular disease (CVD) and lipoprotein(a) (Lp(a)) is an independent risk factor for CVD. 31625055 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE The association between lipoprotein(a) [Lp(a)] levels and the risk of cardiovascular disease is of great interest but still controversial. 31740238 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study. 31185726 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Several lipoprotein(a)-lowering therapies are currently being developed with the long-term goal of reducing cardiovascular disease and mortality; however, the relationship between lipoprotein(a) and mortality is unclear. 30608559 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Lipoprotein(a) as a key target in combined therapeutic approaches for cardiovascular disease. 31530423 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Elevated low-density lipoprotein cholesterol and/or lipoprotein(a) are established risk factors for cardiovascular disease (CVD). 30799420 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Those with evidence of CAD were significantly more likely to be male, inactive, diabetic and with a family history of CVD than participants without CAD.About 20% of patients had lipoprotein(a) (Lp(a)) concentrations above 106.9 nmol/L (fifth quintile). 31481563 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE It is well-known that Lp(a) levels have an impact on increased risk of CVD which is affected by LPA gene. 31113255 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE The causal relationship of lipoprotein(a) with cardiovascular disease has been established. 31577620 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Malondialdehyde, lipoprotein-a, lipoprotein ratios, comprehensive lipid tetrad index and atherogenic index as surrogate markers for cardiovascular disease in patients with psoriasis: a case-control study. 30830310 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Lipoprotein (a) [Lp(a)] is an established causal risk factor for cardiovascular disease (CVD), independently of low-density lipoproteins (LDL) and other risk factors. 31493849 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. 30675027 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Lipoprotein(a) [Lp(a)] has been considered as a causal risk factor for cardiovascular disease (CVD) in the general population and levels vary in different ethnicities. 31683090 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Elevated Lipoprotein(a) (Lp[a]) is a well-known risk factor for cardiovascular disease. 31023762 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 AlteredExpression group BEFREE The greatest frequency of cardiovascular disease (CVD; 69%) was observed in DM[-]EOCHD[+] patients, whose lipoprotein(a) and insulinemia were also highest (81 nmol/L and 140 pmol/L, respectively). 30105804 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Recently, lipoprotein(a) has emerged as an important cardiovascular risk factor and lipoprotein apheresis has been used to decrease lipoprotein(a) concentrations in patients with marked elevations and cardiovascular disease. 31041550 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Elevated serum lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular disease risk. 31220285 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. 30150142 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Clinical trials are under way to lower the lipoprotein (a) (Lp(a)) and its associated oxidized phospholipids, which will provide clinical evidence that targeting inflammation caused by oxidized lipids is a viable approach for CVD. 30946962 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE In patients who cannot be treated adequately by drugs it is possible to reduce increased LDL-C and/or lipoprotein(a) (Lp(a)) values by the use of lipoprotein apheresis (LA) with the potential to decrease severe CVD events in the range of 70%->80%. 31818446 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 Biomarker group BEFREE Background Elevated lipoprotein(a) (Lp(a)), a low-density lipoprotein-like particle bound to the polymorphic apolipoprotein(a) (apo(a)), may be causal for cardiovascular disease. 30897995 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.500 GeneticVariation group BEFREE Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study. 31349819 2019